Companies · Pharmaceuticals

Trxade Group, Inc.

COMMACK · Pharmaceuticals

Diligence memoA one-page analyst read on Trxade Group, Inc. — recommendation, valuation, rhythm, risks.
$74.2M
Total raised · real
11
Rounds
0.8×
Latest step-up
Top 14%
Sector rank · raised
Series C
Latest stage · inferred · Fri Jul 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Trxade Group, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.09× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (25 peers) — value vs value, same stage and era.
Active
  • Last raise 11 mo ago; this sector typically re-raises about every 13 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Trxade Group, Inc. is one of 1610 Pharmaceuticals companies tracked from COMMACK. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2025-07-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2014-01-08 Raised $65M (real) Modeled valuation $2.3B (est)Series C2014Series C · 2014-03-27 Raised $375K (real) Modeled valuation $13M (est)Series C2014Series C · 2014-10-16 Raised $1.1M (real) Modeled valuation $39M (est)Series C2014Series C · 2015-10-22 Raised $452K (real) Modeled valuation $16M (est)Series C2015Series C · 2017-02-28 Raised $251K (real) Modeled valuation $8.8M (est)Series C2017Series C · 2018-07-11 Raised $300K (real) Modeled valuation $11M (est)Series C2018Series C · 2018-10-16 Raised $300K (real) Modeled valuation $11M (est)Series C2018Series C · 2018-11-13 Raised $500K (real) Modeled valuation $18M (est)Series C2018Series C · 2019-07-30 Raised $1.0M (real) Modeled valuation $35M (est)Series C2019Series C · 2024-11-25 Raised $3.3M (real) Modeled valuation $25M (est)Series C2024Series C · 2025-07-18 Raised $1.7M (real) Modeled valuation $10M (est)Series C2025Seed · 2025-07-18 Raised $1.3M (real) Modeled valuation $3.6M (est)Seed2025Cumulative $76M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$64.9M · 2014
Series C extension$375K · 2014
Series C extension$1.1M · 2014
Series C extension$452K · 2015
Series C extension$251K · 2017
Series C extension$300K · 2018
Series C extension$300K · 2018
Series C extension$500K · 2018
Series C extension$1.0M · 2019
Series C extension$3.3M · 2024
Series C extension$1.7M · 2025
Bridge · Series C-stage$1.3M · 2025smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$10.4M
Base estimate est.
$5.6M
Conservative case
$13.7M
Upside case
$11.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series C · modeled $2.3B · 2014-01-082014Series C · modeled $13.2M · 2014-03-27Series C · modeled $38.6M · 2014-10-16Series C · modeled $15.8M · 2015-10-22Series C · modeled $8.8M · 2017-02-28Series C · modeled $10.5M · 2018-07-11Series C · modeled $10.5M · 2018-10-16Series C · modeled $17.5M · 2018-11-13Series C · modeled $35.1M · 2019-07-30Series C · modeled $25.3M · 2024-11-25Series C · modeled $10.4M · 2025-07-18Seed · modeled $3.6M · 2025-07-182025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$6.4M/yr
Capital velocity
12.5 yr
On record since
2014
First round
12
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 9.2× above median
This company$74.2M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.3M
Sector median$46.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$10.4M
Sector median$76.1M

Raised more than 87% of sector peers (real $). Modeled value above 18% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #25 of 25.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)BlossomHill Therapeutics, Inc. · Series C Raised $245.8M · modeled $452.2M (est)Rivus Pharmaceuticals, Inc. · Series C Raised $223.5M · modeled $415.9M (est)Sparrow Pharmaceuticals, Inc. · Series C Raised $73.3M · modeled $386.2M (est)Arthrosi Therapeutics, Inc. · Series C Raised $132.9M · modeled $385.2M (est)Altesa BioSciences, Inc. · Series C Raised $110.0M · modeled $373.5M (est)Mirum Pharmaceuticals, Inc. · Series C Raised $138.5M · modeled $347.9M (est)Eyenovia, Inc. · Series C Raised $66.0M · modeled $312.3M (est)Alveus Therapeutics, Inc. · Series C Raised $56.9M · modeled $297.8M (est)Aeovian Pharmaceuticals, Inc. · Series C Raised $125.0M · modeled $297.5M (est)Curevo, Inc. · Series C Raised $110.0M · modeled $293.0M (est)Neuropathix, Inc. · Series C Raised $51.3M · modeled $270.8M (est)Verrica Pharmaceuticals Inc. · Series C Raised $77.5M · modeled $268.8M (est)Trxade Group, Inc. (this company) Raised $74.2M · modeled $10.4M (est)Trxade Group, Inc.
CompanyStageRaised · realValue · estvs peer med.
BlossomHill Therapeutics, Inc.Series C$245.8M$452.2M3.72×
Rivus Pharmaceuticals, Inc.Series C$223.5M$415.9M3.42×
Sparrow Pharmaceuticals, Inc.Series C$73.3M$386.2M3.18×
Arthrosi Therapeutics, Inc.Series C$132.9M$385.2M3.17×
Altesa BioSciences, Inc.Series C$110.0M$373.5M3.08×
Mirum Pharmaceuticals, Inc.Series C$138.5M$347.9M2.86×
Eyenovia, Inc.Series C$66.0M$312.3M2.57×
Alveus Therapeutics, Inc.Series C$56.9M$297.8M2.45×
Aeovian Pharmaceuticals, Inc.Series C$125.0M$297.5M2.45×
Curevo, Inc.Series C$110.0M$293.0M2.41×
Neuropathix, Inc.Series C$51.3M$270.8M2.23×
Verrica Pharmaceuticals Inc.Series C$77.5M$268.8M2.21×
Trxade Group, Inc. this companySeries C$74.2M$10.4M0.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$64.9M2014-01-08$432.7M$2.3B85%
Series C$375K2014-03-27$2.5M$13.2M85%
Series C$1.1M2014-10-16$7.3M$38.6M85%
Series C$452K2015-10-22$3.0M$15.8M85%
Series C$251K2017-02-28$1.7M$8.8M90%
Series C$300K2018-07-11$2.0M$10.5M90%
Series C$300K2018-10-16$2.0M$10.5M90%
Series C$500K2018-11-13$3.3M$17.5M90%
Series C$1.0M2019-07-30$6.7M$35.1M90%
Series C$3.3M2024-11-25$22.2M$25.3M90%
Series C$1.7M2025-07-18$11.4M$10.4M90%
Seed$1.3M2025-07-18$6.5M$3.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$64.9M2014-01-08
    • First recorded raise — entered as Series C.
    • 28 investors on this round.
  2. Series C$375K2014-03-27
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 173.1× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  3. Series C$1.1M2014-10-16
    • Came back fast: 7 mo vs the ~13 mo sector norm.
    • Round 2.9× larger than the prior — scaling up.
    • Revenue band moved $0–$1M → $1M–$5M.
    • 3 investors on this round.
  4. Series C$452K2015-10-22
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Series C$251K2017-02-28
    • Raised 16 mo later, in step with the ~13 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series C$300K2018-07-11
    • Raised 16 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  7. Series C$300K2018-10-16
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  8. Series C$500K2018-11-13
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 1 investor on this round.
  9. Series C$1.0M2019-07-30
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 1 investor on this round.
  10. Series C$3.3M2024-11-25
    • Raised again after 64 mo — slower than the ~13 mo sector norm.
    • Round 3.3× larger than the prior — scaling up.
    • 2 investors on this round.
  11. Series C$1.7M2025-07-18
    • Raised 8 mo later, in step with the ~13 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  12. Seed$1.3M2025-07-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~13mo cadence
$1.3M
Modeled next size est.range $1.3M$2.1M
0.8×
Last step-up
$6.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael L Peterson3 other2017-02
Michael Peterson2 other2018-07
Charles L. Pope1 other2014-01
Prashant Patel1 other2014-01
Shankar Hariharan1 other2024-11
Donald Fell2015-10
Donald G. Fell2014-01
Fernando Sanchez2015-10
Howard A. Doss2014-01
Howard Doss2015-10
Mayur Doshi2024-11
Mayur G. Doshi2025-07
Narasimhan Mani2024-11
Subbarao G. Jayanthi2025-07
Subbarao Jayanthi2024-11
Suren Ajjarapu2014-01
Surendra Ajjarapu2024-11
Registry & provenance

Trxade Group, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1382574
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gilgamesh Pharma Inc.PharmaceuticalsSeries C$72.7M$10.8Msame sector · same stage
BiomX Inc.PharmaceuticalsSeries C$72.3M$16.9Msame sector · same stage
Cytrellis Biosystems, Inc.Other Health CareSeries C$82.7M$182.0Mnetwork1 shared operator · same stage
Scienture Inc.PharmaceuticalsSeries A$6.0M$185.8Mnetwork1 shared operator · same sector
Emmaus Life Sciences, Inc.PharmaceuticalsSeries B$102.9M$2.9Msame sector
Limerick Biopharma IncPharmaceuticalsSeries B$52.8M$16.3Msame sector
Oragenics IncBiotechnologySeries A$67.4M$6.9Mnetwork1 shared operator
Metabolic Solutions Development Co LlcPharmaceuticalsSeries B$50.1M$6.8Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TruTag Technologies, Inc.PharmaceuticalsSeries B$291.0M87%
RxBio Holdings, Inc.PharmaceuticalsSeries D+$12.0M85%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.0M84%
Pacylex Pharmaceuticals Inc.PharmaceuticalsSeries A$148.1M84%
Acendrx, Inc.PharmaceuticalsSeed$95.1M84%
EPALEX CorpPharmaceuticalsSeries B$5.0M83%
Delex Healthcare Group, Inc.PharmaceuticalsSeries B$340.8M83%
TFF Pharmaceuticals, Inc.PharmaceuticalsSeries B$9.2M83%
Frequently asked
How much funding has Trxade Group, Inc. raised?
Trxade Group, Inc. has raised approximately $74.2M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is Trxade Group, Inc.'s estimated valuation?
Provath's modeled valuation for Trxade Group, Inc. is approximately $10.4M (modeled range $5.6M–$13.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Trxade Group, Inc. at?
Trxade Group, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Jul 18.
What does Trxade Group, Inc. do and where is it based?
Trxade Group, Inc. operates in the Pharmaceuticals sector, based in COMMACK.
Explore related

See where Trxade Group, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Trxade Group, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.